Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 14/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 13/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28255203 | 0.74 | CTSK (0.40) | PTGDR2CYP2C9 | |
| SCHEMBL6502501 | 0.73 | LMNA (0.43) | — | |
| SCHEMBL20542063 | 0.73 | CA1 (0.40) | — | |
| SCHEMBL24408329 | 0.72 | CYP17A1 (0.37) | — | |
| SCHEMBL6544482 | 0.71 | RXRA (0.37) | — | |
| SCHEMBL6557087 | 0.71 | SIGMAR1 (0.42) | SIGMAR1 | |
| SCHEMBL21754350 | 0.70 | MIF (0.38) | PTGDR2 | |
| SCHEMBL21754348 | 0.70 | CA1 (0.36) | PTGDR2 | |
| SCHEMBL6557081 | 0.70 | NPSR1 (0.43) | SIGMAR1 | |
| SCHEMBL27660942 | 0.70 | NQO2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150592-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20130217592-A1 | ARRAYS AND METHODS COMPRISING M. SMITHII GENE PRODUCTS | THE WASHINGTON UNIVERSITY (US) | 2013-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | NR5A2, NR5A1, GPER1 | CYP4A11 58/4885CYP4F2 160/4885PTGDR2 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.